TGA pre submission meetings were originally booked for November so hopefully these are happening shortly with full study results to follow (I suspect they are holding on to these until engagement with TGA).
With flower and capsule products beginning to sell on top of existing Medicabilis products, a reduced admin cost base, studies in Malaysia supporting sales early next year and C-Fit studies progressing towards commercial sales for Aquaphase - exciting times for BOD particularly at a market cap of <$5m. S3 year one gross profits alone are more than likely to eclipse this based on industry estimates of the OTC market and standard industry margins.
Despite the ongoing funding risks, it’s a strong buy for me at this price. If regulatory hurdles are cleared, which we should have more assurance on soon, this will fly.
BOD Price at posting:
2.8¢ Sentiment: Buy Disclosure: Held
(20min delay)